Vascular endothelial growth factor gene therapy - ViroMed

Drug Profile

Vascular endothelial growth factor gene therapy - ViroMed

Alternative Names: VMDA-3601

Latest Information Update: 13 Oct 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical; ViroMed Co Ltd
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders

Most Recent Events

  • 13 Oct 2010 Discontinued - Phase-II for Peripheral arterial occlusive disorders in South Korea (IM)
  • 01 Aug 2007 VMDA 3601 is still in active development
  • 26 Jan 2004 Phase-II clinical trials in Peripheral arterial occlusive disorders in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top